Dermocosmetics Brand Solaana MD Offered for Acquisition

GTT Group, known for patent-backed transactions, is exclusively representing Solaana MD in this acquisition. GTT typically works with corporations and high-net-worth individuals, offering a range of financial services, including investments in mid-market companies. The group's investment arm, GTT Capital, focuses on companies needing capital for expansion, recapitalization, or acquisitions, particularly in Europe and Asia. Solaana MD is a physician-founded dermocosmetics brand with a patented topical Vitamin D delivery system. Their "Healthy Base Layer" cream aims to provide the benefits of Vitamin D without UV exposure, addressing a deficiency that affects an estimated 40% of U.S. adults. The product is designed to be used under sunscreen, bypassing the gastrointestinal system for direct skin-level delivery. The potential acquisition target operates within the $76 billion dermocosmetics market. This market is seeing substantial growth, with the global dermatology market projected to reach $2.75 billion by 2034, exhibiting a CAGR of 6.94%. The dermatology devices market alone was valued at $12.8 billion in 2024 and is expected to reach $36.9 billion by 2034, growing at an 11.5% CAGR. Solaana MD emphasizes clean skincare, using vegan Vitamin D3 and avoiding phthalates, sulfates, dyes, and parabens. The company also operates in a solar-powered facility and uses recyclable packaging. The brand is WBENC-certified as a women-owned business.